Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Aspirin-exacerbated Respiratory Disease

Interventions

DRUG: Dupilumab

Sponsor

Rochester General Hospital